Skvarka Jan

Skvarka Jan is listed in filings as Director at Zentalis Pharmaceuticals, Inc.. This profile follows SEC Form 4 activity through Jun 18, 2025, including purchase activity. Recent filings connect the profile to Zentalis Pharmaceuticals, Inc. (ZNTL) and Monte Rosa Therapeutics, Inc. (GLUE). The current snapshot covers public activity from Jun 13, 2024 to Jun 18, 2025. Reported amounts are shown as $150.7K to $91.9K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.